William Blair Issues Positive Forecast for Glaukos Earnings

Glaukos Co. (NYSE:GKOS) – Stock analysts at William Blair increased their Q4 2024 earnings per share estimates for Glaukos in a research report issued on Tuesday, November 5th. William Blair analyst M. Andrew now anticipates that the medical instruments supplier will post earnings per share of ($0.34) for the quarter, up from their previous forecast of ($0.36). The consensus estimate for Glaukos’ current full-year earnings is ($2.16) per share. William Blair also issued estimates for Glaukos’ Q1 2025 earnings at ($0.33) EPS, Q2 2025 earnings at ($0.25) EPS, Q3 2025 earnings at ($0.23) EPS, Q4 2025 earnings at ($0.24) EPS and FY2025 earnings at ($1.05) EPS.

A number of other equities analysts have also recently issued reports on GKOS. Needham & Company LLC raised their price objective on shares of Glaukos from $131.00 to $137.00 and gave the company a “buy” rating in a research note on Thursday, August 1st. Truist Financial raised their price target on Glaukos from $145.00 to $152.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. Piper Sandler set a $140.00 price target on shares of Glaukos in a report on Thursday, October 17th. JPMorgan Chase & Co. boosted their price objective on shares of Glaukos from $130.00 to $145.00 and gave the company an “overweight” rating in a research report on Tuesday. Finally, StockNews.com upgraded Glaukos from a “sell” rating to a “hold” rating in a report on Monday, October 21st. Four equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $134.55.

Glaukos Stock Performance

GKOS stock opened at $139.33 on Friday. The company has a 50 day moving average price of $129.72 and a 200 day moving average price of $120.48. The stock has a market capitalization of $7.66 billion, a PE ratio of -46.14 and a beta of 1.02. Glaukos has a fifty-two week low of $59.22 and a fifty-two week high of $143.24. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.48 and a quick ratio of 4.67.

Glaukos (NYSE:GKOS) last posted its earnings results on Monday, November 4th. The medical instruments supplier reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.20. Glaukos had a negative return on equity of 20.28% and a negative net margin of 42.43%. The business had revenue of $96.70 million during the quarter, compared to the consensus estimate of $91.50 million. During the same quarter last year, the company earned ($0.50) EPS. Glaukos’s revenue was up 23.9% on a year-over-year basis.

Hedge Funds Weigh In On Glaukos

Several large investors have recently modified their holdings of GKOS. EFG Asset Management North America Corp. increased its holdings in Glaukos by 0.5% during the 2nd quarter. EFG Asset Management North America Corp. now owns 27,205 shares of the medical instruments supplier’s stock worth $3,216,000 after purchasing an additional 128 shares in the last quarter. Values First Advisors Inc. purchased a new stake in Glaukos during the 3rd quarter worth about $25,000. New York State Teachers Retirement System increased its stake in Glaukos by 0.4% in the 3rd quarter. New York State Teachers Retirement System now owns 48,143 shares of the medical instruments supplier’s stock worth $6,272,000 after acquiring an additional 200 shares during the last quarter. KBC Group NV increased its holdings in shares of Glaukos by 16.2% in the 3rd quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier’s stock worth $188,000 after buying an additional 201 shares during the last quarter. Finally, Inspire Investing LLC lifted its stake in Glaukos by 6.9% during the third quarter. Inspire Investing LLC now owns 3,193 shares of the medical instruments supplier’s stock worth $416,000 after purchasing an additional 206 shares during the last quarter. Institutional investors own 99.04% of the company’s stock.

Insider Transactions at Glaukos

In other news, Director Marc Stapley sold 6,250 shares of the firm’s stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $125.93, for a total transaction of $787,062.50. Following the completion of the sale, the director now owns 34,076 shares in the company, valued at approximately $4,291,190.68. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other news, Director Marc Stapley sold 6,250 shares of the business’s stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $125.93, for a total value of $787,062.50. Following the completion of the transaction, the director now directly owns 34,076 shares in the company, valued at approximately $4,291,190.68. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Joseph E. Gilliam sold 5,000 shares of the business’s stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $129.36, for a total value of $646,800.00. Following the transaction, the chief operating officer now directly owns 102,169 shares of the company’s stock, valued at $13,216,581.84. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 16,525 shares of company stock worth $2,142,029. 6.40% of the stock is owned by company insiders.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.